Company Filing History:
Years Active: 2017-2019
Title: Lichun Li – Innovator in Hepatitis B Research
Introduction
Lichun Li, an accomplished inventor based in Bloomington, IN, holds three patents that contribute significantly to the field of hepatitis B research. His innovations focus on therapeutic compounds and diagnostic tools designed to combat hepatitis B viral infections.
Latest Patents
Lichun Li's latest patents include groundbreaking advancements in hepatitis B treatment and diagnosis. The first patent, titled "Hepatitis B viral assembly effectors," discloses novel assembly effector compounds that possess therapeutic effects against hepatitis B virus (HBV) infection. These assembly effector molecules can lead to defective viral assembly and may influence other viral activities linked to chronic HBV infection. Additionally, this patent outlines a synthesis process for these compounds, methods of treatment, and their application in manufacturing medicaments aimed at HBV.
His second patent, "Fluorescent-HAP: a diagnostic stain for HBV cores in cells," focuses on heteroaryldihydropyrimidine (HAP)-based fluorescent stains. These compounds serve as diagnostic reagents, viral-tracking agents, and tools for drug discovery, showcasing their versatility and potential impact in hepatitis B research.
Career Highlights
Lichun Li works with the Indiana University Research and Technology Corporation, where he leverages his expertise to advance scientific discoveries in virology. His contributions are instrumental in developing new approaches for diagnosing and treating hepatitis B.
Collaborations
Throughout his career, Lichun Li has collaborated with noteworthy colleagues, including Adam Zlotnick and William Wilson Turner, Jr. These collaborations highlight his commitment to working alongside other experts in the field to drive forward research and innovation.
Conclusion
Lichun Li is a remarkable inventor whose work in hepatitis B research is shaping the future of treatment and diagnostics. His patented innovations demonstrate a deep understanding of viral biology and a commitment to combating hepatitis B, making him a valuable asset to the scientific community and public health.